The Skin Deep Symposium July 15, 2009 was a great success- watch for information on next year's program, July 21, 2010.

--------------------------------------------------

Friday, January 23, 2009    11:00 am-1:00 pm
EDA Commercialization Center
675 Route 1, North Brunswick, NJ 08902

Diabetes, Dermis & Dollars  

Alice Marcy, Ph. D.

Scientific Operations Officer
Dynamis Therapeutics, Inc.

Dr. Marcy will speak on  the company's technology and its commercial partnerships.

She is a biochemist/molecular biologist who has conducted laboratory research in drug discovery, and evaluated in-licensing opportunities totaling $300 million at Merck. Dr. Marcy holds a graduate degree from Johns Hopkins University and a postdoctoral fellowship from Harvard Medical School.

Dynamis Therapeutics is developing proprietary new drugs to treat chronic inflammatory disease. Its proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone (3DG). Research, originally conducted at the Fox Chase Cancer Center, suggests that elevated 3DG causes metabolic, neurological, and dermatological diseases, ranging from diabetic retinopathy (blindness) and nephropathy (kidney disease) to inflammatory skin conditions and aging.

The Company's first medical products are drugs against dry eye and the complications of diabetes.

Continuing research is funded in part through licensing technology to cosmetics companies, and the commercialization of its patented anti-aging/anti-wrinkling cosmetic cream, MEG 21, through the professional dermatologist/spa market.

 Click Here for an article in U.S. 1 Newspaper

Previous Events:

Tales from the Trenches:
Life Science Consultants' Roundtable
July 9, 2008

Dr. Philip Chaikin, MD

During his 25-year pharma career, Dr. Chaikin held positions in preclinical and clinical development at Kyowa Pharmaceutical, Ortho Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Hoechst Roussel, Rhone Poulenc Rorer and Elan Pharmaceuticals.

He has been involved with the development and launch of several blockbuster and significant drugs, and is now helping international companies address discovery, development, and regulatory challenges in multiple disease and operational areas.

Found in Translation
April 25, 2008

Pat Kelly, Ph.D, of Ballard Spahr, and Serial CEO Paul Hensley

Intellectual Property and Technology Transfer Strategies for Life Science Companies

Build Your Management Team
November 7, 2007

Rick Pinto, of Stevens & Lee, with

Marialice Barone and Jim O'Hara of Barone-O'Hara Associates, and Kristina Siu of UMDNJ and the Association of Women in Science.